139 related articles for article (PubMed ID: 16734723)
1. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist.
Said MM; Hokaiwado N; Tang M; Ogawa K; Suzuki S; Ghanem HM; Esmat AY; Asamoto M; Refaie FM; Shirai T
Cancer Sci; 2006 Jun; 97(6):459-67. PubMed ID: 16734723
[TBL] [Abstract][Full Text] [Related]
2. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of human c-Ha-ras proto-oncogene overexpression on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
Hokaiwado N; Asamoto M; Cho YM; Tsuda H; Shirai T
Cancer Sci; 2003 Dec; 94(12):1042-5. PubMed ID: 14662018
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
Zeng Y; Yokohira M; Saoo K; Takeuchi H; Chen Y; Yamakawa K; Matsuda Y; Kakehi Y; Imaida K
Carcinogenesis; 2005 Jun; 26(6):1109-16. PubMed ID: 15731164
[TBL] [Abstract][Full Text] [Related]
5. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
7. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
Asamoto M; Hokaiwado N; Cho YM; Takahashi S; Ikeda Y; Imaida K; Shirai T
Cancer Res; 2001 Jun; 61(12):4693-700. PubMed ID: 11406539
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.
Cho YM; Takahashi S; Asamoto M; Suzuki S; Inaguma S; Hokaiwado N; Shirai T
Cancer Sci; 2003 Feb; 94(2):153-7. PubMed ID: 12708490
[TBL] [Abstract][Full Text] [Related]
9. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
10. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat.
Wang Z; Luque RM; Kineman RD; Ray VH; Christov KT; Lantvit DD; Shirai T; Hedayat S; Unterman TG; Bosland MC; Prins GS; Swanson SM
Endocrinology; 2008 Mar; 149(3):1366-76. PubMed ID: 18079205
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the response of rat testis and accessory sex organs to treatment with testosterone and the synthetic androgen methyltrienolone (R1881).
van Roijen JH; Ooms MP; Weber RF; Brinkmann AO; Grootegoed JA; Vreeburg JT
J Androl; 1997; 18(1):51-61. PubMed ID: 9089068
[TBL] [Abstract][Full Text] [Related]
12. Influence of atrazine administration and reduction of calorie intake on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
Kandori H; Suzuki S; Asamoto M; Murasaki T; Mingxi T; Ogawa K; Shirai T
Cancer Sci; 2005 Apr; 96(4):221-6. PubMed ID: 15819720
[TBL] [Abstract][Full Text] [Related]
13. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
14. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
15. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
16. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
17. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
18. Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats.
Maezawa H; Komatsu H; Kawaoi A; Ueno A
Int J Urol; 1997 Jul; 4(4):411-6. PubMed ID: 9256333
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of testosterone and of a luteinizing hormone-releasing hormone agonist on androgen receptor content in the ventral prostate of castrated rats.
Fiorelli G; Zoppi S; Kohen F; Motta M
Steroids; 1989; 53(1-2):195-217. PubMed ID: 2505407
[TBL] [Abstract][Full Text] [Related]
20. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
Séguin C; Cusan L; Bélanger A; Kelly PA; Labrie F; Raynaud JP
Mol Cell Endocrinol; 1981 Jan; 21(1):37-41. PubMed ID: 6259002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
